Avalo Therapeutics's total assets for Q2 2024 were $108.31M, a decrease of -12.46% from the previous quarter. AVTX total liabilities were $110.46M for the fiscal quarter, a -53.25% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.